SUPR4B1W

SUPR4B1W is a cyclic macrocyclic peptide designed to inhibit autophagy by specifically binding to and blocking the function of microtubule-associated protein light chain 3 (LC3), a key protein required for autophagosome maturation[1][3]. Its structure confers protease resistance and cell permeability through cyclization and multiple N-methyl amino acid incorporations[1]. SUPR4B1W interacts with LC3 via its Trp1 and Val5 residues, preventing formation of the Atg4:LC3 complex and thus inhibiting C-terminal proteolysis and autophagosome maturation, leading to cell death, particularly when combined with chemotherapy agents such as cisplatin and carboplatin[3]. Developed in preclinical studies, SUPR4B1W shows promise in overcoming chemoresistance in certain cancer models, although it is not yet a marketed pharmaceutical[1][3].

Brand names

SUPR4B1WSUPR-4B1WSUPR 4B1W

Other names

SUPR4B1WSUPR-4B1WSUPR 4B1W